<DOC>
	<DOCNO>NCT01828879</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy tacrolimus ointment treat sign symptom moderate ( medium level seriousness ) severe ( serious , life threaten ) atopic dermatitis ( intensely pruritic [ itch ] , chronic [ last long time ] , inflammatory [ pain swell ] , immunologically base skin disease genetic predisposition [ latent susceptibility disease genetic level ] ) adult participant .</brief_summary>
	<brief_title>An Efficacy Safety Study Tacrolimus Ointment Adult Participants With Atopic Dermatitis</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , prospective ( study follow participant forward time ) , randomize ( like flip coin ) , multi-center study adult participant moderate severe atopic dermatitis . Participants treat 0.1 percent concentration tacrolimus ointment apply twice daily 4 week 1 week affect area define treatment baseline completely clear , whichever first . The study consist 6 visit : pre-study ( optional ) , Baseline Day 1 , Weeks 1 , 2 , 3 4 ( end-of-treatment ) . The ointment apply least 2 hour least 30 minute bath , shower , shave , use sauna , heavy exercise ( i.e . cause sweat ) . On study visit day , ointment apply least 2 hour visit . Efficacy evaluation do subsequent study visit participant receive study drug least 3 consecutive day ( minimum 5 application ) participant receive least 1 application study drug , evaluate safety . Primary efficacy evaluation base Physician 's Global Evaluation Clinical Response ( PhGECR ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Participants diagnosis atopic dermatitis use Hanifin Rajka Criteria ( major criterion : pruritus , lichenification [ crust ] , chronic relapse [ return medical problem ] course , family history atopy minor criterion : xerosis [ dry skin ] , ichthyosis [ skin disorder characterize dryness , roughness , scaliness ] , immediate Type I reactions [ reaction occur within minute exposure challenge antigen : substance recognize immune system induce immune reaction ] skin test antigen ) involve least 10 percent body surface area Participants skin disorder severe heart , liver , kidney lung diseases Participants give informed consent Female participant childbearing potential must negative pregnancy test Participant meet follow washout requirement ( washout period range 142 day ) study : 1 day ( nonmedicated topical [ apply skin ; surface ] agent ) ; 7 day ( terfenadine , nonsedating systemic antihistamine [ drug use treat allergic reaction ] , topical corticosteroid ( steroid hormone ) , H1 H2 antihistamine , antimicrobial [ drug kill bacteria germ ] , medicate topical agent ) ; 14 day ( intranasal [ delivery medication nasal mucosa ] and/or inhale corticosteroid ) ; 28 day ( light treatment [ ultra violet ray A , ultra violet ray B ] , nonsteroidal immunosuppressant [ drug suppress body 's immune response , use transplantation disease cause disordered immunity ] , investigational drug systemic corticosteroid ) ; 42 day ( astemizole ) Participant skin disorder atopic dermatitis area treat Participant pigmentation extensive scarring pigment lesion ( abnormal area tissue , wound , sore , rash , boil ) area treat would interfere rating efficacy parameter Participant clinically infect atopic dermatitis baseline Participant systemic disease , include cancer ( abnormal tissue grow spread body kill ) history cancer Human Immunodeficiency Virus ( HIV : lifethreatening infection get infect person 's blood sex infect person ) , would contraindicate ( medical reason prevent person use certain drug treatment ) use immunosuppressant Participant know hypersensitivity ( altered reactivity antigen ) macrolides ( drug exhibit antibiotic property ) excipient ointment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Dermatitis , Atopic</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>